Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview

被引：28
|
作者：
Rezaee, Haleh [1 ,2 ]
Pourkarim, Fariba [2 ]
Pourtaghi-Anvarian, Samira [2 ]
Entezari-Maleki, Taher [2 ]
Asvadi-Kermani, Touraj [3 ]
Nouri-Vaskeh, Masoud [4 ,5 ]
机构：
[1] Tabriz Univ Med Sci, Infect Dis & Trop Med Res Ctr, Tabriz, Iran
[2] Tabriz Univ Med Sci, Fac Pharm, Dept Clin Pharm, Tabriz, Iran
[3] Tabriz Univ Med Sci, Fac Med, Dept Surg, Tabriz, Iran
[4] Tabriz Univ Med Sci, Immunol Res Ctr, Daneshgah St,POB 5166614766, Tabriz, Iran
[5] Universal Sci Educ & Res Network USERN, Network Immun Infect Malignancy & Autoimmun NIIMA, Tehran, Iran
来源：
PHARMACOLOGY RESEARCH & PERSPECTIVES | 2021年 / 9卷 / 01期
关键词：
adverse reactions; chloroquine; COVID-19; drug-drug interaction; Kaletra; remdesivir; PLUS RIBAVIRIN TREATMENT; PHARMACOKINETIC INTERACTIONS; HEPATITIS-C; RHEUMATOID-ARTHRITIS; PROTEASE INHIBITORS; COINFECTED PATIENTS; HEALTHY-VOLUNTEERS; CHLOROQUINE; TOCILIZUMAB; METABOLISM;
D O I：
10.1002/prp2.705
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Drug-drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID-19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT-prolongation, retinopathy, increased risk of infection, and hepatotoxicity. This review focuses on summarizing DDIs for candidate medications used for COVID-19 in order to minimize the adverse reactions.
引用
收藏
页数：18
相关论文
共 50 条
  • [21] Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications
    Jain, Shreshta
    Potschka, Heidrun
    Chandra, P. Prarthana
    Tripathi, Manjari
    Vohora, Divya
    EPILEPSY RESEARCH, 2021, 174
  • [22] High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment
    Macias, Juan
    Pinilla, Ana
    Lao-Dominguez, Francisco A.
    Corma, Anais
    Contreras-Macias, Enrique
    Gonzalez-Serna, Alejandro
    Gutierrez-Pizarraya, Antonio
    Fernandez-Fuertes, Marta
    Morillo-Verdugo, Ramon
    Trigo, Marta
    Real, Luis M.
    Pineda, Juan A.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [23] Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir
    Brandariz-Nunez, David
    Correas-Sanahuja, Marcelo
    Guarc, Eva
    Picon, Rafael
    Garcia, Barbara
    Gil, Rocio
    MEDICINA CLINICA, 2020, 155 (07): : 281 - 287
  • [24] An update on drug-drug interactions for care of the acutely ill in the era of COVID-19
    Patanwala, Asad E.
    Jager, Nynke G. L.
    Radosevich, John J.
    Bruggemann, Roger
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2023, 80 (19) : 1301 - 1308
  • [25] COVID-19 in a young liver transplant recipient: caution for drug-drug interactions
    Dajti, Elton
    Cristini, Francesco
    Tamanini, Giacomo
    Cescon, Matteo
    Bazzoli, Franco
    Tame, Mariarosa
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2020, 29 (03) : 470 - 470
  • [26] Drug-Drug Interactions and the Clinical Tolerability of Colchicine Among Patients With COVID-19
    Alfehaid, Lama S.
    Farah, Subrina
    Omer, Azza
    Weber, Brittany N.
    Alkhezi, Omar
    Tawfik, Yahya M. K.
    Shah, Amil M.
    Libby, Peter
    Buckley, Leo F.
    JAMA NETWORK OPEN, 2024, 7 (09)
  • [27] Evaluation of potential drug-drug interactions and polypharmacy in hospitalized COVID-19 patients
    Kilit, Turkan Pasali
    Ozyigit, Filiz
    Erarslan, Sertas
    Onbasi, Kevser
    AFRICAN HEALTH SCIENCES, 2022, 22 (04) : 597 - 606
  • [28] Drug-drug interactions in a kidney transplant patient with COVID-19: A case report
    Khamas, Shahriyar Shahbazi
    Jafari, Atefeh
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 203 - 204
  • [29] Efficacy, Safety, and Drug-Drug Interactions for Insomnia Therapy in COVID-19 Patients
    Saputra, Billy Dwi
    Levita, Jutti
    Mustarichie, Resmi
    JOURNAL OF MULTIDISCIPLINARY HEALTHCARE, 2022, 15 : 137 - 152
  • [30] Drug-drug interaction with oral antivirals for the early treatment of COVID-19
    Vuorio, Alpo
    Raal, Frederick
    Kovanen, Petri T.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 127 : 171 - 172
12345